New daunorubicin-protein conjugates were prepared by covalently linking the antitumor drug to various test proteins via its methylketone side chain. Attachment of daunorubicin to proteins was achieved by nucleophylic substitution reaction of the 14-bromo derivative of the drug, under mild coupling conditions. In contrast to conventional methods, this procedure did not involve reaction or modification of the amino sugar. As expected, the covalent linkage of the drug was generally associated with an appreciable reduction in the drug cytotoxicity to HeLa cells in vitro. The possible advantages of this method for coupling to specific protein carriers are discussed.
Get full access to this article
View all access options for this article.
References
1.
ArcamoneF.: New antitumor anthracyclines.Lloydia, 40: 45–46, 1977.
2.
ArcamoneF., FranceschiG., MinghettiA., PencoS., RedaelliS., Di MarcoA., CasazzaA.M., DasdiaT., Di FronzoG., GiulianiF., LenazL., NeccoA., SoranzoC.: Synthesis and biological evaluation of some 14-0-acyl derivatives of adriamycin.J. Med. Chem., 17: 335–337, 1974.
3.
ArcamoneF., FranceschiG., PencoS.: Process for the preparation of adriamycin, adriamycinone and adriamycin derivatives. U. S. Patent no. 3,803,124 (April 9, 1974).
4.
Di MarcoA., CasazzaA.M., SoranzoC., PratesiG.: Effect of various substitutions in positions 1, 2, 3 and 4 of 4-demethoxydaunorubicin and 4-demethoxyadriamycin.Cancer Chemother. Pharmacol., 1: 249–254, 1978.
5.
GhoseT., BlairA.H.: Antibody-linked cytotoxic agents in the treatment of cancer: Current status and future prospects.J. Natl. Cancer Inst., 61: 657–676, 1978.
6.
GregoriadisG.: Targeting of drugs.Nature, 265: 407–411, 1977.
7.
HurwitzE., LevyR., MaronR., WilchekM., ArnonR., SelaM.: The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities.Cancer Res., 35: 1175–1181, 1975.
8.
KitaoT., HattoriK.: Concanavalin A as a carrier of daunomycin.Nature, 265: 81–82, 1977.
9.
LeeF.H., BercziI., FujimotoS., SehonA.H.: The use of antifibrin antibodies for the destruction of tumor cells.III. Complete regression of MC-D sarcoma in guinea pigs by conjugates of daunomycin with antifibrin antibodies. Cancer Immunol. Immunother., 5: 201–206, 1978.
10.
LeeF.H., HwangK.M.: Antibodies as specific carriers for chemotherapeutic agents.Cancer Chemother. Pharmacol., 3: 17–24, 1979.
11.
LevinY., SelaB.A.: Studies on the amino acids and peptide derivatives of daunorubicin.FEBS Lett., 98: 119–122, 1979.
12.
SzekerkeM., DriscollJ.S.: The use of macromolecules as carriers of antitumor drugs.Eur. J. Cancer, 13: 529–537, 1977.
13.
TrouetA.: Increased selectivity of drugs by linking to carriers.Eur. J. Cancer, 14: 105–111, 1978.
ZuninoF., Di MarcoA., VelcichA.: Steric influence of the orientation of the primary amino group at position 3 of the sugar moiety of anthracycline antibiotics in DNA binding properties.Cancer Lett., 3: 271–275, 1977.
16.
ZuninoF., GambettaR., Di MarcoA., VelcichA., ZaccaraA., QuadrifoglioF., CrescenziV.: The interaction of adriamycin and its β anomer with DNA.Biochim. Biophys. Acta, 476: 38–46, 1977.
17.
ZuninoF., GambettaR., Di MarcoA., ZaccaraA.: Interaction of daunomycin and its derivatives with DNA.Biochim. Biophys. Acta, 277: 489–498, 1972.
